Thus, PmTriTNE showed unique functionality by engaging T cells and tumor cells while simultaneously blocking PD‐L1 to efficiently activate and expand CD8+ TILs and thus elicit a potent antitumor response in the TME. The gene discussed is CD274; the disease is neoplasm.